QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 29 November 2021Portfolio NewsQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
- 23 November 2021Portfolio NewsLoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
- 17 November 2021Portfolio NewsAlpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
- 10 November 2021Portfolio NewsSitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer
- 9 November 2021Portfolio NewsWelsh, Carson, Anderson & Stowe Acquires Majority Stake in Leiters
- 4 November 2021SV NewsVibrato Medical announced that Paul A. LaViolette has been appointed to its board of directors.
- 2 November 2021Portfolio NewsNitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
- 29 October 2021Portfolio NewsBioventus Completes the Acquisition of Misonix
- 26 October 2021Portfolio NewsXilio Therapeutics Announces Closing of Initial Public Offering
- 21 October 2021Portfolio NewsZerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions
- 21 October 2021Portfolio NewsXilio Therapeutics Announces Pricing of Initial Public Offering
- 18 October 2021Portfolio NewsXilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors